Shire rejects $63bn takeover proposal from Takeda
The rare disease drug maker revealed that the Japanese pharma company made three offers recently. Takeda’s latest offer came on 13 April, which was £46.50 per each share
Lyell Immunopharma has entered into a definitive agreement for the acquisition of ImmPACT Bio USA, a move that is expected to prioritise its pipeline to focus on chimeric antigen receptor (CAR) T-cell therapies.